Sarcomatoid carcinoma of the lung natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(12 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Sarcomatoid carcinoma of the lung}}


{{CMG}}; {{AE}}{{Trusha}}
{{CMG}}; {{AE}} {{Trusha}}


==Overview==
==Overview==
 
The majority of patients with sarcomatoid carcinoma of the lung remain are initially asymptomatic. Early clinical features include [[chronic cough]], [[hemoptysis]], [[dyspnea]], [[weight loss]], and [[fatigue]]. If left untreated, patients with sarcomatoid carcinoma of the lung may develop local invasion and distant metastasis. Majority of the patients with central sarcomatoid carcinoma of the lung may develop distant metastasis to [[Esophageal cancer|esophagus]], [[Small intestine cancer|jejunum]], [[Colorectal cancer|rectum]], and [[Renal cancer|kidney]]. Sarcomatoid carcinoma of lung located in the periphery of lungs tends to be diagnosed later in the advanced stages with the large size and metastasis to the [[Pleural cavity|pleura]] and chest wall. Common complications include [[respiratory failure]], [[Pneumonia|recurrent pneumonia]], and [[Metastasis|distant metastasis]]. Prognosis is generally poor. The 3-year and 5-year survival rates are 35.8 and 28.7%.
Sarcomatoid carcinoma of the lung progresses slowly and is followed by local invasion to lymph nodes, chest wall, pleura and distant [[metastasis]]. Sarcomatoid carcinoma of the lung is a type of non-small cell lung cancer. Non-small cell lung cancer is locally aggressive malignancy, which commonly occurs in adult patients between 65 to 74 years. Common sites of metastasis include [[adrenal gland|the adrenal gland]], [[Bone tumors|bone]], [[brain]], and [[liver]]. Complications of non-small cell lung cancer include [[respiratory failure|acute respiratory failure]], [[respiratory acidosis]], [[pleural effusion|malignant pleural effusion]], [[metastases]], and [[pneumonia]]. The 3-year and 5-year survival rates for patients with sarcomatoid cancer of lung are 35.8% and 28.7%. Features associated with worse prognosis are presence of lymphatic invasion, location of lesion, and presence of regional or distant metastases. Prognosis is generally regarded as poor.


==Natural History==
==Natural History==
The majority of patients with non-small cell lung cancer are initially asymptomatic.<ref name="pmid17356101">{{cite journal |vauthors=Soares M, Darmon M, Salluh JI, Ferreira CG, Thiéry G, Schlemmer B, Spector N, Azoulay E |title=Prognosis of lung cancer patients with life-threatening complications |journal=Chest |volume=131 |issue=3 |pages=840–6 |year=2007 |pmid=17356101 |doi=10.1378/chest.06-2244 |url=}}</ref>
The majority of patients with non-small cell lung cancer are initially asymptomatic.<ref name="pmid17356101">{{cite journal |vauthors=Soares M, Darmon M, Salluh JI, Ferreira CG, Thiéry G, Schlemmer B, Spector N, Azoulay E |title=Prognosis of lung cancer patients with life-threatening complications |journal=Chest |volume=131 |issue=3 |pages=840–6 |year=2007 |pmid=17356101 |doi=10.1378/chest.06-2244 |url=}}</ref>
*The symptoms of non-small cell lung cancer usually develop in adult patients between 65 to 74 years.
*The majority of patients with sarcomatoid carcinoma of the lung remain are initially asymptomatic.
*Initially, patients complain of [[Cough|chronic cough]], [[diaphoresis]], and [[weight-loss]].
*Early clinical features include chronic [[cough]], [[hemoptysis]], [[dyspnea]], [[weight loss]] and [[fatigue]].<ref>{{cite book |last1=Travis WD |last2=Brambilla E |last3=Müller-Hermelink K |last4=Harris C |last5=Kleihues C |last6=Sobin P |title=World Health Organization Classification of Tumours; Pathology and genetics of tumors of the lung, pleura, thymus, and heart |publisher=IARC Press |orig-year=2004 |pages=53-58|chapterurl=https://www.iarc.fr/wp-content/uploads/2018/07/BB10.pdf |isbn=ISBN 92 832 2418 3}}</ref><ref>{{cite book |last1=Travis WD |last2=Brambilla E |last3=Müller-Hermelink K |last4=Harris C |last5=Kleihues C |last6=Sobin P |title=World Health Organization Classification of Tumours; Pathology and genetics of tumors of the lung, pleura, thymus, and heart |publisher=IARC Press |orig-year=2004 |pages=53-58|chapterurl=https://www.iarc.fr/wp-content/uploads/2018/07/BB10.pdf |isbn=ISBN 92 832 2418 3}}</ref>
*If left untreated, patients with non-small cell lung cancer may develop local invasion to lymph nodes and distant metastasis.
*If left untreated, patients with sarcomatoid carcinoma of the lung may develop local invasion and distant [[metastasis]].
*Common sites of metastasis include the [[adrenal gland]], [[Bone tumors|bone]], [[brain]], and [[liver]].
*The majority of patients with central sarcomatoid carcinoma of the lung may develop distant metastasis to [[esophagus]], [[jejunum]], [[rectum]], and kidney.
*Sarcomatoid carcinoma of lung located in the periphery of lungs tends to be diagnosed later in the advanced stages with the large size and [[metastasis]] to the pleura and chest wall.


==Complications==
==Complications==
Common complications of non-small cell lung cancer, include:<ref name="pmid17356101">{{cite journal |vauthors=Soares M, Darmon M, Salluh JI, Ferreira CG, Thiéry G, Schlemmer B, Spector N, Azoulay E |title=Prognosis of lung cancer patients with life-threatening complications |journal=Chest |volume=131 |issue=3 |pages=840–6 |year=2007 |pmid=17356101 |doi=10.1378/chest.06-2244 |url=}}</ref>
Common complications of sarcomatoid carcinoma of the lung, include:<ref name="pmid17356101">{{cite journal |vauthors=Soares M, Darmon M, Salluh JI, Ferreira CG, Thiéry G, Schlemmer B, Spector N, Azoulay E |title=Prognosis of lung cancer patients with life-threatening complications |journal=Chest |volume=131 |issue=3 |pages=840–6 |year=2007 |pmid=17356101 |doi=10.1378/chest.06-2244 |url=}}</ref>
*[[Respiratory failure|Acute respiratory failure]]
*[[Respiratory failure|Acute respiratory failure]]
*[[Respiratory acidosis]]
*[[Respiratory acidosis]]
Line 23: Line 24:


==Prognosis==
==Prognosis==
Prognosis of sarcomatoid carcinoma of the lung depends on the origin of the tumor, histological type, and stage.<ref name="pmid17356101">{{cite journal |vauthors=Soares M, Darmon M, Salluh JI, Ferreira CG, Thiéry G, Schlemmer B, Spector N, Azoulay E |title=Prognosis of lung cancer patients with life-threatening complications |journal=Chest |volume=131 |issue=3 |pages=840–6 |year=2007 |pmid=17356101 |doi=10.1378/chest.06-2244 |url=}}</ref>
[[Prognosis]] of sarcomatoid carcinoma of the lung depends on the origin of the tumor, [[histological]] type, and stage.<ref name="pmid17356101">{{cite journal |vauthors=Soares M, Darmon M, Salluh JI, Ferreira CG, Thiéry G, Schlemmer B, Spector N, Azoulay E |title=Prognosis of lung cancer patients with life-threatening complications |journal=Chest |volume=131 |issue=3 |pages=840–6 |year=2007 |pmid=17356101 |doi=10.1378/chest.06-2244 |url=}}</ref>
* Prognosis of sarcomatoid carcinoma of the lung is generally poor.
* Prognosis of sarcomatoid carcinoma of the lung is generally poor.
* The 3-year and 5-year survival rates for patients with sarcomatoid cancer of lung are 35.8 and 28.7%.<ref name="RoeselTerjung2016">{{cite journal|last1=Roesel|first1=Christian|last2=Terjung|first2=Sarah|last3=Weinreich|first3=Gerhard|last4=Hager|first4=Thomas|last5=Chalvatzoulis|first5=Eleftherios|last6=Metzenmacher|first6=Martin|last7=Welter|first7=Stefan|title=Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages|journal=Interactive CardioVascular and Thoracic Surgery|year=2016|pages=ivw392|issn=1569-9293|doi=10.1093/icvts/ivw392}}</ref>
* The 3-year and 5-year survival rates for patients with sarcomatoid cancer of lung are 35.8 and 28.7%.<ref name="RoeselTerjung2016">{{cite journal|last1=Roesel|first1=Christian|last2=Terjung|first2=Sarah|last3=Weinreich|first3=Gerhard|last4=Hager|first4=Thomas|last5=Chalvatzoulis|first5=Eleftherios|last6=Metzenmacher|first6=Martin|last7=Welter|first7=Stefan|title=Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages|journal=Interactive CardioVascular and Thoracic Surgery|year=2016|pages=ivw392|issn=1569-9293|doi=10.1093/icvts/ivw392}}</ref>
* Non-small cell lung cancer [[survival rate]] ranges from 1% to 52% (stage I to stage IV).  
* [[Non-small cell lung cancer]] [[survival rate]] ranges from 1% to 52% (stage I to stage IV).  
* The recurrence rate of non-small cell lung cancer is 24%.
* The development of complications is associated with worse prognosis.<ref name="pmid21976848">{{cite journal |vauthors=Muduly D, Deo S, Subi Ts, Kallianpur A, Shukla N |title=An update in the management of malignant pleural effusion |journal=Indian J Palliat Care |volume=17 |issue=2 |pages=98–103 |year=2011 |pmid=21976848 |pmc=3183615 |doi=10.4103/0973-1075.84529 |url=}}</ref>
Features associated with worse prognosis, include:
***Presence of lymphatic invasion
***Unfavorable genetic expression profile
***Location of lesion
***Performance status
***Presence of satellite lesions
***Presence of regional or distant metastases
 
The table below summarizes the 5-year survival rate according to non-small cell lung cancer stage:
{| style="border: 0px; font-size: 90%; margin: 3px; width: 150px" align="center"
 
|+
! style="background: #4479BA; width: 20px;" | {{fontcolor|#FFF|Stage}}
! style="background: #4479BA; width: 75px;" | {{fontcolor|#FFF|5-year survival rate}}
|-
| style="padding: 5px 5px; background: #DCDCDC;" |IA
| style="padding: 5px 5px; background: #F5F5F5;" |49%
|-
| style="padding: 5px 5px; background: #DCDCDC;" |IB
| style="padding: 5px 5px; background: #F5F5F5;" |45%
|-
| style="padding: 5px 5px; background: #DCDCDC;" |IIA
| style="padding: 5px 5px; background: #F5F5F5;" |30%
|-
| style="padding: 5px 5px; background: #DCDCDC;" |IIB
| style="padding: 5px 5px; background: #F5F5F5;" |31%
|-
| style="padding: 5px 5px; background: #DCDCDC;" |IIIA
| style="padding: 5px 5px; background: #F5F5F5;" |14%
|-
| style="padding: 5px 5px; background: #DCDCDC;" |IIIB
| style="padding: 5px 5px; background: #F5F5F5;" |5%
|-
| style="padding: 5px 5px; background: #DCDCDC;" |IV
| style="padding: 5px 5px; background: #F5F5F5;" |1%
|}


==References==
==References==
{{reflist|2}}
{{reflist|2}}


{{WikiDoc Help Menu}}
{{WH}}
{{WikiDoc Sources}}
{{WS}}
{{Tumors}}
 
[[Category:Disease]]
[[Category:Types of cancer]]
[[Category:Pulmonology]]
[[Category:Lung cancer]]
[[Category:Oncology]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Medicine]]
[[Category:Pulmonology]]
[[Category:Surgery]]
[[Category:Surgery]]

Latest revision as of 21:26, 9 January 2019

Sarcomatoid Carcinoma of the Lung Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sarcomatoid Carcinoma of the Lung from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

Echocardiography and Ultrasound

CT-Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sarcomatoid carcinoma of the lung natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sarcomatoid carcinoma of the lung natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sarcomatoid carcinoma of the lung natural history, complications and prognosis

CDC on Sarcomatoid carcinoma of the lung natural history, complications and prognosis

Sarcomatoid carcinoma of the lung natural history, complications and prognosis in the news

Blogs on Sarcomatoid carcinoma of the lung natural history, complications and prognosis

Directions to Hospitals Treating Sarcomatoid carcinoma of the lung

Risk calculators and risk factors for Sarcomatoid carcinoma of the lung natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Trusha Tank, M.D.[2]

Overview

The majority of patients with sarcomatoid carcinoma of the lung remain are initially asymptomatic. Early clinical features include chronic cough, hemoptysis, dyspnea, weight loss, and fatigue. If left untreated, patients with sarcomatoid carcinoma of the lung may develop local invasion and distant metastasis. Majority of the patients with central sarcomatoid carcinoma of the lung may develop distant metastasis to esophagus, jejunum, rectum, and kidney. Sarcomatoid carcinoma of lung located in the periphery of lungs tends to be diagnosed later in the advanced stages with the large size and metastasis to the pleura and chest wall. Common complications include respiratory failure, recurrent pneumonia, and distant metastasis. Prognosis is generally poor. The 3-year and 5-year survival rates are 35.8 and 28.7%.

Natural History

The majority of patients with non-small cell lung cancer are initially asymptomatic.[1]

  • The majority of patients with sarcomatoid carcinoma of the lung remain are initially asymptomatic.
  • Early clinical features include chronic cough, hemoptysis, dyspnea, weight loss and fatigue.[2][3]
  • If left untreated, patients with sarcomatoid carcinoma of the lung may develop local invasion and distant metastasis.
  • The majority of patients with central sarcomatoid carcinoma of the lung may develop distant metastasis to esophagus, jejunum, rectum, and kidney.
  • Sarcomatoid carcinoma of lung located in the periphery of lungs tends to be diagnosed later in the advanced stages with the large size and metastasis to the pleura and chest wall.

Complications

Common complications of sarcomatoid carcinoma of the lung, include:[1]

Prognosis

Prognosis of sarcomatoid carcinoma of the lung depends on the origin of the tumor, histological type, and stage.[1]

  • Prognosis of sarcomatoid carcinoma of the lung is generally poor.
  • The 3-year and 5-year survival rates for patients with sarcomatoid cancer of lung are 35.8 and 28.7%.[4]
  • Non-small cell lung cancer survival rate ranges from 1% to 52% (stage I to stage IV).

References

  1. 1.0 1.1 1.2 Soares M, Darmon M, Salluh JI, Ferreira CG, Thiéry G, Schlemmer B, Spector N, Azoulay E (2007). "Prognosis of lung cancer patients with life-threatening complications". Chest. 131 (3): 840–6. doi:10.1378/chest.06-2244. PMID 17356101.
  2. Travis WD; Brambilla E; Müller-Hermelink K; Harris C; Kleihues C; Sobin P. https://www.iarc.fr/wp-content/uploads/2018/07/BB10.pdf |chapterurl= missing title (help) (PDF). World Health Organization Classification of Tumours; Pathology and genetics of tumors of the lung, pleura, thymus, and heart. IARC Press. pp. 53–58. ISBN ISBN 92 832 2418 3 Check |isbn= value: invalid character (help).
  3. Travis WD; Brambilla E; Müller-Hermelink K; Harris C; Kleihues C; Sobin P. https://www.iarc.fr/wp-content/uploads/2018/07/BB10.pdf |chapterurl= missing title (help) (PDF). World Health Organization Classification of Tumours; Pathology and genetics of tumors of the lung, pleura, thymus, and heart. IARC Press. pp. 53–58. ISBN ISBN 92 832 2418 3 Check |isbn= value: invalid character (help).
  4. Roesel, Christian; Terjung, Sarah; Weinreich, Gerhard; Hager, Thomas; Chalvatzoulis, Eleftherios; Metzenmacher, Martin; Welter, Stefan (2016). "Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages". Interactive CardioVascular and Thoracic Surgery: ivw392. doi:10.1093/icvts/ivw392. ISSN 1569-9293.

Template:WH Template:WS Template:Tumors